 Daré Bioscience, Inc. DARE, a leader in womens health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center, double-blind, placebo-controlled Phase 3 clinical study of DARE-BV1 for the treatment of bacterial vaginosis. DARE-BV1 is an investigational thermosetting bioadhesive hydrogel containing clindamycin phosphate 2 being evaluated as a one-time, vaginally-administered treatment for bacterial vaginosis. The DARE-BVFREE study is expected to enroll approximately 240 participants, ages 12 and older, diagnosed with bacterial vaginosis across multiple clinical sites in the United States. 